ArticleBMC anesthesiology2025
Impact of the enhanced recovery after surgery (ERAS) protocol on 3-year survival and outcomes following esophagectomy: a retrospective cohort study of 124 patients.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Too fast or too slow?: Considerations in the era of enhanced recovery and FAST Track for upper GI surgery.Surgical endoscopy · 2026Article
- Optimizing perioperative care in esophagectomy: a narrative review.Journal of thoracic disease · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe benefits of the enhanced recovery after surgery (ERAS) protocol across surgeries are well documented, but its impact on esophageal cancer surgery remains understudied. This study compared the 3-year survival rates of esophagectomy patients treated with and without ERAS at a tertiary care hospital.
methodsA retrospective analysis of 124 elective esophagectomy patients (Jan 2017-Jan 2022) was conducted. Patients with distant metastasis or had concurrent hypopharynx cancer that needed pharyngectomy were excluded from analysis. Patients treated before April 2019 received standard care, while those treated from April 2019 followed the ERAS protocol. Multivariate Cox regression analysis identified potential prognostic factors for overall survival. Survival associations were determined using the Kaplan-Meier(K-M) method and log-rank tests. The primary outcome was 3-year overall survival, and the secondary outcomes were postoperative intensive care unit (ICU) stay, hospital length of stay (LOS), and complications.
resultsWe analyzed 58 patients in the control group and 66 patients in the ERAS group. The ERAS group demonstrated significantly lower 3-year overall mortality compared to the control group in multivariate Cox regression (adjusted hazard ratio: 0.44, 95% CI: 0.22-0.88, p = 0.020). Advanced pathologic cancer stage and neoadjuvant chemoradiation therapy (CCRT) were independent negative prognostic factors (adjusted hazard ratio for advanced pathological stage: 2.91, 95% CI: 1.27-6.66, p = 0.011; for neoadjuvant CCRT: 2.73, 95% CI: 1.23-6.08, p = 0.013). Kaplan-Meier survival analysis showed a significantly higher 3-year survival rate in the ERAS group compared to the control group (70.2% vs. 47.4%, p = 0.043). Subgroup analysis revealed significant survival benefits of ERAS in patients with preoperative albumin concentration < 4 g/dl, advanced pathological stage and aged < 65 years. Additionally, the ERAS group had significantly shorter ICU stays (mean difference: -2.3 days, p < 0.001), shorter hospital LOSs (mean difference: -4.9 days, p < 0.001), while postoperative complication rates were comparable between two groups.
conclusionsThe ERAS protocol in esophagectomy patients was associated with shorter ICU and hospital stays and emerged as an independent positive prognostic factor for 3-year overall survival. These results suggest ERAS might indirectly improve long-term survival by accelerating recovery, thereby enabling patients to better tolerate and complete essential postoperative oncological treatments. Nevertheless, larger prospective studies are required to validate this interpretation conclusively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.